US5292756A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel sulfonamide fibrinogen receptor antagonists
Assignee: Medicure International Inc
•
Filing: 1992-03-25
•
Granted: 1994-03-08
•
Expires: 2012-03-25
Abstract
Abstract A series of non-peptide derivatives of the formula <IMAGE>
Inventors
- 👤 Mark E. Duggan
- 👤 Melissa S. Egbertson
- 👤 Wasyl Halczenko
- 👤 George D. Hartman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 07:52
CPC Classifications
C; C07; C07C; C07C311/00; C07C311/01; C07C311/02; C07C311/03; C07C311/06; A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61P; A61P43/00; A61P7/00; A61P7/02; C07C311/12; C07C311/13; C07D; C07D211/00; C07D211/04; C07D211/06; C07D211/08; C07D211/18; C07D211/20; C07D211/22; C07D409/00; C07D409/02; C07D409/12; C07D413/00; C07D413/02; C07D413/12; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
87 words
A compound of the structural formula ##STR216## and the pharmaceutically acceptable salts thereof, wherein R 4 is aryl, C 1-10 alkyl, or C 4-10 aralkyl, wherein aryl is phenyl, pyridyl, thienyl, tetrazole or oxazale; R 5 is ##STR217## wherein R 8 is hydroxy or C 1-10 alkyloxy, ##STR218## wherein R 9 and R 10 are selected from the group consisting of hydrogen, C 1-10 alkyl and phenyl C 1-4 alkyl; Z is ##STR219## p is zero or one; and m is an integer from two to six.
Claim 2
Dependent Claim
87 words
A compound of the structural formula ##STR216## and the pharmaceutically acceptable salts thereof, wherein R 4 is aryl, C 1-10 alkyl, or C 4-10 aralkyl, wherein aryl is phenyl, pyridyl, thienyl, tetrazole or oxazale; R 5 is ##STR217## wherein R 8 is hydroxy or C 1-10 alkyloxy, ##STR218## wherein R 9 and R 10 are selected from the group consisting of hydrogen, C 1-10 alkyl and phenyl C 1-4 alkyl; Z is ##STR219## p is zero or one; and m is an integer from two to six.
Claim 3
Dependent Claim
86 words
A compound of claim 1, ##STR220## and the pharmaceutically acceptable salts thereof, wherein R 4 is aryl, C 1-10 alkyl, or C 4-10 aralkyl, wherein aryl is phenyl, pyridyl, thiophenyl, tetrazole, or oxazole; R 5 is ##STR221## wherein R 8 is hydroxy or C 1-10 alkyloxy, ##STR222## wherein R 9 and R 10 are selected from the group consisting of hydrogen, C 1-10 alkyl and phenyl C 1-4 alkyl; Z is O; p is zero or one; and m is an integer from two to six.
Claim 4
Dependent Claim
12 words
A compound as claimed in claim 2, of the structural formula ##STR223##
Claim 5
Dependent Claim
12 words
A compound as claimed in claim 2, of the structural formula ##STR224##
Claim 6
Dependent Claim
12 words
A compound as claimed in claim 2, of the structural formula ##STR225##
Claim 7
Dependent Claim
36 words
A compound of claim 1 selected from the group consisting of 2-S-(2-Styrylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; 2-S-(Phenylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; 2-S-(2-Phenethylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; 2-S-(2-Thienylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]1-n-butylsulfonylamino)}ethanephosphonic acid ethyl ester; {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]1n-butylsulfonylamino)}ethanephosphonic acid; and Ethyl-2-S-Benzylsulfonylamino-3-[4-(piperidin-4-yl)butyloxyphenyl]propionate; 2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)-1,1-dimethyl-butyloxyphenyl]propionic acid; and 3-S-(Butylsulfonylamino)-4-[4-piperidin-4-yl)butyloxyphenyl]butanoic acid.
Claim 8
Dependent Claim
16 words
A pharmaceutical composition, comprising a compound as claimed in claim 2, and a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
16 words
A pharmaceutical composition, comprising the compound as claimed in claim 3, and a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
16 words
A pharmaceutical composition, comprising the compound as claimed in claim 4, and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
16 words
A pharmaceutical composition, comprising the compound as claimed in claim 5, and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
16 words
A pharmaceutical composition, comprising a compound as claimed in claim 6, and a pharmaceutically acceptable carrier.
Claim 13
Dependent Claim
35 words
A method of blocking fibrinogen from acting at its platelet receptor site in a mannal, comprising the step of administering to said mammal a pharmacologically effective amount of a compound as claimed in claim 2.
Claim 14
Dependent Claim
12 words
The method as claimed in claim 12, wherein said compound is ##STR226##
Claim 15
Dependent Claim
12 words
The method as claimed in claim 12, wherein said compound is ##STR227##
Claim 16
Dependent Claim
12 words
The method as claimed in claim 12, wherein said compound is ##STR228##
Claim 17
Dependent Claim
38 words
The method as claimed in claim 12, wherein said compound is selected from 2-S-(2-Styrylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; 2-S-(Phenylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid hydrochloride; 2-S-(2-Phenethylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; 2-S-(2-Thienylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride; {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]-1-n-butylsulfonylamino)}ethanephosphonic acid ethyl ester; {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]-1-n-butylsulfonylamino)}ethanephosphonic acid; and Ethyl-2-S-Benzylsulfonylamino-3-[4-(piperidin-4-yl)butyloxyphenyl]propionate; 2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)-1,1-dimethyl-butyloxphenyl]propionic acid; and 3-S-(Butylsulfonylamino)-4-[4-piperidin-4-yl)butyloxyphenyl]butanoic acid.
References Cited (Backward Citations)
US4243807A
Cited
US4122255A
Cited
US4098889A
Cited
US4622331A
Cited
EP0040111A1
Cited
US5030654A
Cited
US4977165A
Cited
EP0449079A2
Cited
US5064814A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-03-07 | 1997-09-06 | 1998-03-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-03-07 | 2001-09-06 | 2002-03-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-03-07 | 2005-09-06 | 2006-03-08 | $7700.00 | Window Closed / Lapsed |